Fundraisings and IPOs

Date: 2015-11-10

Type of information: Series C financing round

Company: Miragen Therapeutics (USa - CO)

Investors: MRL Ventures (USA - MA) Brace Pharma Capital (USA - MA) JAFCO Co (Japan) MP Healthcare Venture Management (USA - MA) Atlas Venture (USA - MA) Boulder Ventures (USA - CO) Remeditex Ventures (USA - TX) Amgen Ventures (USA - CA)

Amount: $41 million

Funding type: series C financing round

Planned used: miRagen Therapeutics plans to use the proceeds from this financing round to advance two product candidates, MRG-106 and MRG-201, into clinical development this year.  

Others:

• • On November 10, 2015 , miRagen Therapeutics announced a Series C Preferred Stock financing with gross proceeds of $41 million, including conversion of outstanding notes. The financing was co-led by MRL Ventures, a venture fund of Merck&Co, and JAFCO, who were joined by other new investors Brace Pharma Capital and MP Healthcare Venture Management. Existing investors Atlas Venture, Boulder Ventures, Remeditex Ventures, Amgen Ventures and others, also participated in the financing.
• In conjunction with the financing, Joshua Resnick, M.D., president of MRL Ventures, will join the miRagen Board of Directors.

Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Fibrotic diseases - Inflammatory diseases

Is general: Yes